BIOMARIN PHARMACEUTICAL INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M |
| Cost of revenue | $717.4M | $580.2M | $532.1M | $503.0M | $470.5M |
| Cash from operations | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M |
| Capital expenditure | $103.0M | $85.4M | $96.7M | $121.0M | $95.6M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M |
| Share repurchases | — | — | — | $0 | $0 |
| Impairments | $125.0M | $19.9M | $38.6M | $0 | $0 |
| Total assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B |
| Total liabilities | $1.5B | $1.3B | $1.9B | $1.8B | $1.7B |
| Total debt | $600.0M | $600.0M | $1.1B | $1.1B | $1.1B |
Shares outstanding 193.3M · Free float 80.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.